Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Galena Biopharma (NASDAQ: GALE ) advanced as much as 28% after the biopharmaceutical company focused on developing cancer therapies received two price target hikes from Wall Street firms and announced the first patient enrollment in a phase 2 clinical trial for its GALE-301 treatment.
So what: GALE-301 is a cancer immunotherapy that targets the folate binding protein that is overexpressed in breast, ovarian, and endometrial cancer. Immunotherapy research (teaching the body's immune system to recognize and fight back against cancer cells) was very popular among investors in 2013, and the start of a pivotal phase 2 study is certain to excite shareholders. Two price target hikes following this news are also giving shares a lift. Maxim Group raised its price target to $9 from $6, while Piper Jaffray boosted its price target to $7 from $2.75.
Now what: Although shareholders are clearly excited about its FBP immunotherapy, much of Galena's valuation is baked into the success of NeuVax which is currently in phase 3 trials. Unfortunately, the breast cancer trial involving NeuVax is going to take years, so investors will be waiting quite some time without many catalysts. I'm not saying NeuVax won't be successful, but this mammoth rally in Galena's share price is likely unwarranted until we get to see that top-line phase 3 NeuVax data.
Here's a company you should be following closely, instead
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.